<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04427241</url>
  </required_header>
  <id_info>
    <org_study_id>kuhrm2020no1</org_study_id>
    <nct_id>NCT04427241</nct_id>
  </id_info>
  <brief_title>Combination Treatment With Cerebrolysin and Amantadine on Patients Who Stays in Prolonged Disorders of Consciousness Due to Severe Traumatic Brain Injury</brief_title>
  <official_title>Combination Treatment With Cerebrolysin and Amantadine on Prolonged Disorders of Consciousness in Patients With Severe Traumatic Brain Injury: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Konkuk University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ever Neuro Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Konkuk University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Object: To demonstrate the combined effect of cerebrolysin and amantadine on prolonged
      disorders of consciousness in patients with severe traumatic brain injury Participants:
      patients with prolonged disorders of consciousness due to severe traumatic brain injury
      Intervention: amantadine only (100mg to 200mg bid) or cerebrolysin only (30ml qd) or
      amantadine (100mg to 200mg bid) plus cerebrolysin (30ml qd) Comparison: amantadine only group
      versus cerebrolysin only group versus amantadine plus cerebrolysin group Outcome: Coma
      Recovery Scale-revised, FDG-PET signal
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coma Recovery Scale - revised</measure>
    <time_frame>2 days after randomization</time_frame>
    <description>Assessing the degree of consciousness impairment after traumatic brain injury</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Coma Recovery Scale - revised</measure>
    <time_frame>8 days after randomization</time_frame>
    <description>Assessing the degree of consciousness impairment after traumatic brain injury</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Coma Recovery Scale - revised</measure>
    <time_frame>22 days after randomization</time_frame>
    <description>Assessing the degree of consciousness impairment after traumatic brain injury</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positron Emitting Tomography</measure>
    <time_frame>2 days after randomization</time_frame>
    <description>Assessing the degree of brain neural network activity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positron Emitting Tomography</measure>
    <time_frame>8 days after randomization</time_frame>
    <description>Assessing the degree of brain neural network activity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positron Emitting Tomography</measure>
    <time_frame>22 days after randomization</time_frame>
    <description>Assessing the degree of brain neural network activity</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Brain Injuries, Traumatic</condition>
  <condition>Disorder of Consciousness</condition>
  <arm_group>
    <arm_group_label>Amantadine plus cerebrolysin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Amantadine only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cerebrolysin only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amantadine Sulfate plus Cerebrolysin</intervention_name>
    <description>Amantadine plus cerebrolysin : amantadine 100mg to 200mg bid plus cerebrolysin 30ml qd</description>
    <arm_group_label>Amantadine plus cerebrolysin</arm_group_label>
    <other_name>Cerebrolysin only</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amantadine Sulfate</intervention_name>
    <description>Amantadine only : amantadine 100mg to 200mg bid</description>
    <arm_group_label>Amantadine only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cerebrolysin</intervention_name>
    <description>Cerebrolysin only : cerebrolysin 30ml qd</description>
    <arm_group_label>Cerebrolysin only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with Severe traumatic brain injury (GCS â‰¤8, best available score within 24hrs)

          -  TBI Confirmed with CT or MRI

          -  at least 4 weeks after traumatic event

          -  vegetative state or minimally conscious state secondary to TBI (assessed by CRS-R)

          -  Patient between 19 and 64 years of age

          -  Written informed consent obtained from the patient or legally authorized
             representative

        Exclusion Criteria:

          -  with epileptiform discharge confirmed by EEG

          -  with hydrocephalus

          -  with parenchymal defect

          -  with advanced liver, kidney, cardiac or pulmonary disease

          -  with history of advanced cancer within 2 years

          -  history of alcohol or substance abuse or dependence within the past two years (DSM-V
             criteria)

          -  any significant systemic illness (or unstable medical condition that could lead to
             difficulties complying with the protocol

          -  history of treatment with antidepressants, antipsychotic drugs, nootropic drugs,
             vasodilators

          -  contraindication from amantadine or cerebrolysin

          -  current enrolment in another therapeutic study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Konkuk University Medical Center Research Coordinating Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Mi Soo Jang, Ph.D.</last_name>
      <phone>20305474</phone>
      <phone_ext>+822</phone_ext>
      <email>rcc@kuh.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Lee S, Lee HH, Lee Y, Lee J. Additive effect of cerebrolysin and amantadine on disorders of consciousness secondary to acquired brain injury: A retrospective case-control study. J Rehabil Med. 2020 Feb 27;52(2):jrm00025. doi: 10.2340/16501977-2654.</citation>
    <PMID>32057086</PMID>
  </reference>
  <reference>
    <citation>Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A, Eifert B, Long D, Katz DI, Cho S, Yablon SA, Luther M, Hammond FM, Nordenbo A, Novak P, Mercer W, Maurer-Karattup P, Sherer M. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med. 2012 Mar 1;366(9):819-26. doi: 10.1056/NEJMoa1102609.</citation>
    <PMID>22375973</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 3, 2020</study_first_submitted>
  <study_first_submitted_qc>June 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Konkuk University Medical Center</investigator_affiliation>
    <investigator_full_name>Jongmin Lee, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Consciousness Disorders</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amantadine</mesh_term>
    <mesh_term>Cerebrolysin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

